MedTrace Logo

Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation

NCT01941394 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2013-09-13

No results posted yet for this study

Summary

Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and treatment.

Conditions

  • Graft-versus-host Disease
  • Relapse

Interventions

BIOLOGICAL

Mesenchymal stem cells

Mesenchymal stem cells infusion

Sponsors & Collaborators

  • National Research Center for Hematology, Russia

    lead NETWORK

Principal Investigators

  • Elena Parovichnikova, Prof MD PhD · National Research Center for Hematology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01941394 on ClinicalTrials.gov